Since 2015, we have helped biotech and pharma companies discover novel oncology targets and advance cancer immunotherapies toward IND through tailored preclinical studies.
In clinical trials, we support cancer centers and industry sponsors with biomarker analysis in peripheral and tumor samples — informing patient stratification and characterizing treatment response.
Alban Bessede, founder and CEO, on the three types of questions Explicyte has been answering for biotech and pharma sponsors since 2015 — and on the data science layer that ties them together.
Human FFPE Archives
Identify and characterize candidate oncology targets across tumor and normal human tissues to inform early portfolio decisions.
Cell-based & patient-derived models
Assess the anti-tumor efficacy, safety, and mechanism of action of your candidate(s) in 2D/3D immuno-oncology models.
Patient samples
Develop and apply tissue and peripheral biomarkers to study patient stratification, pharmacodynamics and treatment response across oncology trials.
We don't have salespeople. Once the NDA is signed, a PhD-level scientist explores the options with you to meet your scientific objectives within your timeline and budget. No overselling—we go into the detail and weigh the trade-offs together.
We have a deep catalog of established assays and platforms, but we're not a portfolio CRO. Each study protocol is customized to your specific question rather than fitted to something off the shelf.
We stay in touch through regular updates and interim reports, so the study can be adjusted as preliminary results come in—no surprises at the end.
We don't just hand over raw data. Our in-house data scientists deliver publication-ready figures with full materials and methods, the study director prepares a discussion of the results, and we review everything with your team at the close of the study.
For ten years we've played the long game: solid data that meets industry and academic standards, and scientific relationships built on trust. 80% of our business comes from returning sponsors.
Explicyte is a preclinical and translational CRO specialized in precision oncology and immuno-oncology. We support drug developers from target and biomarker discovery through preclinical efficacy and mechanism-of-action studies, and into translational research and clinical trials with multiomics, digital pathology and bioinformatics.
Yes. We support sponsors from early discovery through preclinical studies designed to advance oncology programs toward IND, and into clinical-stage translational biomarker studies. In clinical trials, we support patient-stratification research, pharmacodynamic monitoring and pre/post-treatment response characterization.
Depending on the project, we work with human and mouse FFPE tissue, fresh or frozen specimens, blood-derived samples such as plasma and PBMCs, and 2D or 3D immune–tumor co-culture models. Our team helps define the most appropriate experimental and analytical strategy according to the samples available and the study objectives.
We combine preclinical oncology models with advanced technologies for tissue, cellular and peripheral biomarker analysis. Our capabilities include IHC and multiplex immunofluorescence, bulk and single-cell transcriptomics, spatial transcriptomics, proteomics, flow cytometry and multiomics data integration. Explicyte is also a 10x Genomics Certified Service Provider for Xenium, Visium HD and Chromium X.
Yes. We support tissue and peripheral biomarker studies in oncology trials, including patient-stratification research, pharmacodynamic monitoring and pre/post-treatment analyses. Tissue studies can include IHC and multiplex IF, while peripheral and multiomic studies can combine approaches such as single-cell RNA sequencing, multiplex flow cytometry, proteomics and spatial transcriptomics. Defined tissue-biomarker development and testing activities can be performed within our ISO-certified quality framework.
Yes. Our in-house data science team can analyze datasets generated either by Explicyte or by external partners, including digital IHC/mIF images, Xenium, Visium HD, Chromium X, GeoMx and bulk RNA-seq data. Services can range from preprocessing and QC to downstream analyses, data integration and publication-ready figures.
Explicyte is an oncology-focused CRO combining target discovery, preclinical development, translational biomarker services and multiomics analysis within one scientific organization. Since 2015, we have worked with biotech, pharma and cancer-center partners on oncology programs spanning early discovery through clinical translational research, contributing to more than 40 peer-reviewed publications since 2020.
Yes. Explicyte works internationally with biotech, pharmaceutical and translational research teams across Europe, North America and Asia-Pacific. In France, we collaborate with leading cancer centers including Institut Bergonié and Gustave Roussy, as well as AI and biotech companies such as Cure51, Kainova Therapeutics, MaaT Pharma and Bioptimus. Internationally, our work includes collaborations with centers such as Memorial Sloan Kettering Cancer Center and co-authored ASCO and AACR studies with pharmaceutical sponsors in the US and Europe. We also have experience supporting biotech companies in Japan, South Korea and Australia.
Explicyte is an independent, privately owned CRO working on a fee-for-service basis. We work under strict confidentiality and do not retain rights to our clients’ IP or seek royalties on the programs we support. Our role is to provide high-quality scientific services and decision-ready data aligned with our clients’ objectives.
Yes. This is a core part of how we work. After reviewing your project, a PhD-level scientist explores different strategies to best address your biological question while optimizing cost and turnaround time. We then discuss the different options with your team and refine the study design accordingly. We can also tailor the reporting schedule, project coordination, and data analysis plan to your specific needs.
We use study-specific qualification criteria, standardized procedures, appropriate assay controls and documented QC throughout our workflows. Defined tissue-biomarker development and testing activities are covered by our ISO 13485 and ISO 9001-certified quality management system, while other preclinical and multiomics services follow their respective controlled internal QC procedures.
Contact us to discuss your oncology research or drug-development project. An NDA can be put in place before you share confidential information about your target, indication, candidate, samples, objectives, timeline or budget. A PhD-level study lead will then review your requirements and develop a study plan tailored to your scientific objectives.
